Status:

RECRUITING

Efficacy of Carminal in Helicobacter Pylori Gastritis

Lead Sponsor:

Catalysis SL

Conditions:

H Pylori Gastritis

H Pylori Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control g...

Detailed Description

Helicobacter pylori-induced gastritis is an infectious disease based on objective pathological criteria. After the successful eradication of the infection, the recovery of the mucosa occurs through a ...

Eligibility Criteria

Inclusion

  • Patients aged 18 years or older
  • Patients with clinical symptoms of dyspepsia
  • Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology
  • Patients who give written informed consent to participate in the study

Exclusion

  • Patients with peptic ulcer disease
  • Patients with previous gastric surgery
  • Patients with current malignancy or the history of any previous malignancies
  • Patients taking another investigational product, or have taken any investigational product in the last year
  • Patients with known hypersensitivity to any ingredients found in the investigational product.
  • Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence to the requirements of the clinical trial, or any other special condition that, according to the physician's judgement, jeopardises the patient's health or life during participation in the trial.
  • Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.
  • Patients with human immunodeficiency virus (HIV).

Key Trial Info

Start Date :

August 4 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 5 2026

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT07179237

Start Date

August 4 2025

End Date

October 5 2026

Last Update

September 17 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Clinical Center of Serbia - Clinic for Gastroenterohepatology

Belgrade, Central Serbia, Serbia, 11000

2

Zvezdara Medical Center - Department of Gastroenterology

Belgrade, Central Serbia, Serbia, 11000